Glicentin is enzymatically stable, inhibits feeding and improves glucose tolerance and beta-cell function through GLP-1, GIP and glucagon receptor signalling

Purpose Glicentin (GLIC) is a major secretory product of intestinal L-cells whose physiological actions remain unclear. Circulating GLIC increases after gastric bypass and is associated with metabolic improvement. We investigated whether GLIC exerts integrated effects on beta-cell function and metabolism, comparing its signalling profile with GLP-1 and oxyntomodulin (OXM). Methods The effects of the three peptides on glucose tolerance, plasma insulin and food intake were assessed in vivo , alongside peptide stability in mouse plasma. Insulin secretion was measured in isolated islets, while real-time cAMP and cytosolic Ca² + dynamics were monitored using fluorescent sensors. Receptor involvement was examined using pharmacological antagonists and stably expressing cell lines. Results GLIC was highly protease-resistant, with no detectable degradation after 4 h in mouse plasma, unlike OXM and GLP-1. In mice, GLIC improved glucose tolerance, enhanced glucose-stimulated insulin secretion and reduced food intake, with effects broadly comparable to GLP-1 and OXM. GLIC stimulated insulin secretion from murine islets and BRIN-BD11 cells at concentrations ≥10 nmol/L and increased islet-cell cAMP and cytosolic Ca² + . Effects were attenuated by GLP-1R and GIPR blockade, with additional GCGR involvement. Accordingly, GLIC stimulated cAMP through all three receptors. GLIC also promoted beta-cell proliferation and reduced cytokine-induced apoptosis. Conclusion GLIC exerts integrated metabolic and beta-cell effects despite low receptor potency. Its marked plasma stability and distinct signalling profile suggest that receptor potency alone does not predict biological activity. GLIC warrants further investigation in human and disease-relevant models.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-18
DOI
https://doi.org/10.3389/fendo.2026.2006139
Primary Topic
Pancreatic function and diabetes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Glicentin is enzymatically stable, inhibits feeding and improves glucose tolerance and beta-cell function through GLP-1, GIP and glucagon receptor signalling

Nigel Irwin, Vaibhav Dubey, Ananyaa Sridhar, Andrei I. Tarasov et al.
2 links
Frontiers in Endocrinology
Pancreatic function and diabetes
article

Glicentin is enzymatically stable, inhibits feeding and improves glucose tolerance and beta-cell function through GLP-1, GIP and glucagon receptor signalling

Nigel Irwin, Vaibhav Dubey, Ananyaa Sridhar, Andrei I. Tarasov, Peter R. Flatt, Dawood Khan, Asif Ali
article en

Abstract

Purpose Glicentin (GLIC) is a major secretory product of intestinal L-cells whose physiological actions remain unclear. Circulating GLIC increases after gastric bypass and is associated with metabolic improvement. We investigated whether GLIC exerts integrated effects on beta-cell function and metabolism, comparing its signalling profile with GLP-1 and oxyntomodulin (OXM). Methods The effects of the three peptides on glucose tolerance, plasma insulin and food intake were assessed in vivo , alongside peptide stability in mouse plasma. Insulin secretion was measured in isolated islets, while real-time cAMP and cytosolic Ca² + dynamics were monitored using fluorescent sensors. Receptor involvement was examined using pharmacological antagonists and stably expressing cell lines. Results GLIC was highly protease-resistant, with no detectable degradation after 4 h in mouse plasma, unlike OXM and GLP-1. In mice, GLIC improved glucose tolerance, enhanced glucose-stimulated insulin secretion and reduced food intake, with effects broadly comparable to GLP-1 and OXM. GLIC stimulated insulin secretion from murine islets and BRIN-BD11 cells at concentrations ≥10 nmol/L and increased islet-cell cAMP and cytosolic Ca² + . Effects were attenuated by GLP-1R and GIPR blockade, with additional GCGR involvement. Accordingly, GLIC stimulated cAMP through all three receptors. GLIC also promoted beta-cell proliferation and reduced cytokine-induced apoptosis. Conclusion GLIC exerts integrated metabolic and beta-cell effects despite low receptor potency. Its marked plasma stability and distinct signalling profile suggest that receptor potency alone does not predict biological activity. GLIC warrants further investigation in human and disease-relevant models.

Frontiers in EndocrinologyVol. 17
University of Ulster (GB)
Ulster University
Good health and well-being
Pancreatic function and diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon